CHRM2 and neoplasm: There was mostly no significant difference between receptor gene expression and tumor features in lung (LUAD and LUSC) cancer adjusted for the patient stage; however, CHRM2 expression showed a significant (p< 0.05) increased risk in LUSC; the Kaplan–Meier (KM) curves indicated that CHRM2 showed a significant (p < 0.01) difference between low and high expression in stage 3 and 4 in LUSC (B).